Platform funding forms part of the Hub’s vision including knowledge transfer and ensuring that results translate to UK and LMIC vaccine markets.
Vax-Hub Feasibility Studies
In June 2020, the Vax-Hub launched a call for proposals for feasibility studies aligned to its aims and primarily of benefit to low- and middle-income countries (LMICs). We are pleased to announce that following our review process, seven projects were awarded funding.
|Phenotypeca Ltd and University of Oxford||Improving VLP vaccine production from baker's yeast|
|University of Leeds and CPI||Scale-up of bioproduction process in Pichia pastoris of a stabilised VLP vaccine candidate for poliomyeletis|
|Vironova and UCL||Validation of the MiniTEM system as an analytical quality control tool for vaccine and viral vector manufacturing|
|University of Teesside|
The application of mass spectrometry approaches to profile, monitor and localise host cell protein products in adenovirus-based vaccine manufacture
|PT BioFarma and UCL|
Optimisation of upstream process for recombinant COVID-19 expressed in Pichia pastoris
|University of Oxford and UCL||COVID-19 vaccine formulation|
Vax-Hub Interaction Vouchers
In February 2020, the Vax-Hub launched a call for proposals for interaction vouchers to support or encourage collaboration between its academic and industrial partners. We are pleased to announce that following our review process, six projects were awarded funding.
|Hilleman Labs and UCL||Establishing the use of microscale chromatography-for downstream process optimization of Group B streptococcus polysaccharides|
|Phenotypeca Ltd and University of Oxford||Exploiting the genetic diversity of Saccharomyces cerevisiae for VLP production|
Sartorius Stedim Biotech and University of Oxford
|Cost of goods evaluation of adenovirus-based vaccine against Coronavirus|
|Sartorius Stedim Biotech and University of Oxford||Improving scalability and productivity of an adenovirus-based vaccine against Coronavirus|
Univercells, University of Leeds and UCL
|Proof of principle synthesis of polio virus-like particles in an E. coli cell-free manufacturing platform|
|Vironova and UCL||MiniTEM analysis: characterisation of Viral Vaccines, Vectors and VLPs|
Platform funding has been awarded to members of the Vax-Hub Users Group only. If you are not currently a member of the Hub but would be interested in joining to access this and other Hub benefits, please contact email@example.com